Bystolic Drug Companies Noncompete Agreements Antitrust Class Action

When it’s time for a “blockbuster” drug’s patent to expire, makers of generics are normally in a hurry to create their own versions. However, the complaint for this antitrust class action alleges that those involved with the drug Bystolic entered into noncompete agreements with potential competitors, to delay the entry of generics into the market.  Read more

Bottle of Bystolic